Tata Elxsi and Dräger collaborate to drive critical care innovation in India
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
The facility will manufacture tablets, capsules, and injections for the oncology segment
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
The report underscores significant advancements in healthcare delivery, showcasing how GenAI facilitates improved diagnostic accuracy, operational efficiency and patient engagement
The surgeons were able to remove the entire breast while preserving the nipple through tiny hidden incisions
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
Lonza plans to invest approximately CHF 500 million to upgrade the facility
A five-day inspection was concluded successfully with no critical and no major observations raised
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Subscribe To Our Newsletter & Stay Updated